PTO/SB/30 (07-0)

Approved for use trinuing of 73.12.012. Owld both -003-10.015. U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1. 5. no persons are required to respond to a collection of information unless it contains a valid OMB control number.				
Request	Application Number	10/581,34	_	
for Continued Examination (RCE) Transmittal	Filing Date		November 20, 2004	
	First Named Inventor	Christian	Christian FUNKE	
	Art Unit	1614	1614	
Mail Stop RCE Commissioner for Patents	Examiner Name	Blakely I	Blakely III, Nelson Clarence	
P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket Numb	er 2400.042	2400.0420000/RWE/L-Z	
This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1 5, or to any design application. See instruction Sheet for RCEs (not to be submitted to the USPTQ) on page 2.				
Submission required under 37 CFR 1.114 Note. If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.				
Consider the arguments in the Appeal Brief or Reply Brief previously filed on Other				
b. X Enclosed I. X Amendment/Reply iii, X Information Disdosure Statement (IDS) ii. X Affidavit(s)/ Declaration(s) IV. Other				
Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) Ditter				
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled. The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled. The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The Director is heraby authorized to charge the following fees, any underpayment of fees, or credit any overpayments, to Deposit Account No. 19-0036 The Director is heraby authorized to Charge the following fees, and the feet of the fee				
i. X RCE fee required under 37 CFR 1.17(e)				
ii. X Extension of time fee (37 CFR 1.136 and 1.17)				
iii. Other				
b. Check in the amount of \$enclosed				
c. X Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Signature L. L. XIOU		Date	Sept. 4. 2009	
Name (Print/Type) Lei Zhou		Registration No.	48,291	
CERTIFICATE OF MAILING OR TRANSMISSION				
I hereby certify that this correspondence is being deposled with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Tradomark Office on the date shown below.				
Signature	Ts	ate		
Name (Print/Type) This collection of information is required by 37 CFR 1.114. The information	tion is required to obtain or retain a	benefit by the public	which is to file (and by the USPTO	

to process) an application. Confidentially is governed by 36 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 cm/minute to complicate including gathering repeating and submitting the completed application from the but USPTO. Three will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademan Office, U.S. Department of Commerce, P.O. Box 14500, Alexandria, VA 2231-1450. DONTS EN DEESE ORCHIVETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patients, P.O. Box 14500, Alexandria, VA 2231-1450. DONTS EN DEESE ORCHIVETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patients, P.O. Box 14500, Alexandria, VA 2231-1450.